SCHEMBL4572187

SCHEMBL4572187

CCCN(C)c1ncnc2[nH]cnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.45
MAP3K5 Q99683 1/20 0.45
STK4 Q13043 2/20 0.43
STK3 Q13188 2/20 0.43
HSD17B10 Q99714 1/20 0.43
NCOA1 Q15788 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
LRRK2 Q5S007 2/20 0.37
CHEK1 O14757 2/20 0.37
AURKA O14965 2/20 0.37
PDPK1 O15530 1/20 0.37
CHEK2 O96017 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
PRKACA P17612 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
MARK3 P27448 1/20 0.37
RPS6KA3 P51812 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5019519 0.87 HSD17B10 (0.39) HTTMAP3K5STK4STK3HSD17B10
SCHEMBL21814339 0.85 HTT (0.58) HTTMAP3K5STK4STK3HSD17B10
SCHEMBL4572193 0.83 HTT (0.51) HTTMAP3K5STK4STK3HSD17B10
SCHEMBL8826203 0.80 CDK1 (0.35) HTTMAP3K5STK4STK3HSD17B10
SCHEMBL9193680 0.80 SLC6A2 (0.41) HTTMAP3K5STK4STK3HSD17B10
SCHEMBL4569246 0.79 NUDT1 (0.41) HTTMAP3K5HSD17B10NCOA1SMN1; SMN2
Dimethyladenine SCHEMBL152593 0.79 LRRK2 (0.52) HTTMAP3K5STK4STK3HSD17B10
SCHEMBL5019515 0.78 HTT (0.41) HTTMAP3K5STK4STK3HSD17B10
SCHEMBL4572189 0.78 HTT (0.40) HTTMAP3K5NCOA1SMN1; SMN2NCOA3
Dimethyladenine SCHEMBL11157543 0.78 LRRK2 (0.50) HTTMAP3K5STK4STK3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB HTT 823/4885MAP3K5 53/4885STK4 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.